Among patients treated for metastatic breast cancer, 40% switched to ABP 980.
A study of the trastuzumab biosimilar ABP 980 (Kanjinti) in Europe found strong uptake patterns, according to an abstract presentation at the 2020 San Antonio Breast Cancer Symposium.
ABP 980 is approved in Europe and the United States for the treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer and metastatic gastric cancer. Investigators sought to understand the real-world application of this product in clinical treatment of patients with breast cancer.
They enrolled patients 18 years or older with a history of breast cancer of any disease or treatment phase, seeking primarily to understand patient demographics and disease characteristics. Exploratory end points included cardiac dysfunction, infusion-related problems, other adverse events, and other safety issues. Efficacy was a secondary end point.
Enrollment included 135 women from Poland, Italy, the Netherlands, France, and Spain, mostly from hospital sites, both academic and public or private. The mean patient age was 58.3 years.
The investigators said 28% of sites had policies on biosimilar use and that 36% of patients were informed they were being started on a biosimilar, with 34% being notified what brand of biosimilar would be used. Twenty-two percent, 27%, 13%, and 28% of patients had stage I, II, III, or IV disease, respectively, at the time ABP 980 was initiated. They also said 68% of patients had estrogen/progesterone receptor–positive tumors. All patients (n = 73) who had been evaluated for Eastern Cooperative Oncology Group performance had a score of 0 or 1.
There was roughly equal use of ABP 980 across treatment settings: neoadjuvant, 39%; adjuvant 30%; and metastatic, 30%.
Among patients who received treatment for metastatic breast cancer (n = 41), 56% and 20% received it for frontline and second-line treatment, respectively. The investigators said that 40% (n = 54) of patients switched to ABP 980 from another trastuzumab product. Of those, 44% switched from the intravenous form of the originator biologic and 15% switched from the subcutaneous form. Most who switched to the subcutaneous form were receiving treatment for metastatic disease.
The investigators concluded there was ABP 980 “uptake across a mixture of institution types and breast cancer treatment settings, including those with curative potential.” The study is ongoing.
Reference
Kufel-Grabowska J, San T, Bernardo A, et al. Patterns of use of a trastuzumab biosimilar (ABP 980) in patients with HER2+ breast cancer treated in clinical practice in Europe: An interim analysis from an observational chart review study (GARDENIA). Poster presented at: San Antonio Breast Cancer Symposium; December 8-11, 2020. PS10-50.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.